Brainpod - The Neuropsychopharmacology Podcast

Systemic lupus erythematosus (SLE) causes significant long-term morbidity and mortality, particularly in children. There is some evidence that the innate immune system, in particular neutrophil activity, can be compromised in adult-onset lupus. Yet there is a paucity of data on neutrophil activity in pediatric SLE. 

This month on Pediapod, we join Early Career Investigator, Rakesh Kumar Pilania, an assistant professor at the postgraduate Institute of Medical Education and Research in Chandigarh, India to discuss his study of neutrophil activity in patients with pediatric SLE and what it reveals about the etiology of this condition.

Read the full article here: https://www.nature.com/articles/s41390-022-02055-2

Neutrophil function in pediatric lupus.

Adolescent consumption of caffeine, the most commonly used psychoactive stimulant in the world, has increased strikingly in recent years. Caffeine use has been associated with illicit drug use and risky behaviors, but whether consumption of caffeine during adolescence has effects on the mature brain is controversial. In this podcast, author Ryan Bachtell discusses his recent study, which found that consumption of caffeine by male adolescent rats results in enduring neurobiological effects in a key reward area in the brain and an increased sensitivity to cocaine in adulthood.
http://www.nature.com/npp/index.html

Brainpod: Caffeine consumption in adolescents

In this issue of Neuropsychopharmacology Reviews, entitled Neurodevelopment and the Origins of Brain Disorders, subject discipline experts provide both experimental highlights and perspectives on the current understanding of basic mechanisms of neurodevelopment, the influence of developmental disruptions on childhood and adult-onset brain and behavioral disorders, and the emerging promise of translation into treatments. In this podcast, the editors of this year's volume, Pat Levitt (Simms/Mann Chair in Development Neurogenetics, Children's Hospital Los Angeles) and Jeremy Veenstra-VanderWeele (Mortimer D Sackler Associate Professor of Psychiatry, Columbia University/New York State Psychiatric Institute), discuss the recent research and its future applications.
http://www.nature.com/npp/index.html

Brainpod: Neurodevelopment and the Origins of Brain Disorders

Marijuana use for medical purposes is becoming increasingly common in the U.S., and doctors prescribe it for ills ranging from headaches to insomnia. And yet, there is little scientific data supporting its medical use. In this podcast, Drs. Margaret Haney and Eden Evins discuss the relationship between cannabis use and two psychiatric disorders: post-traumatic stress disorder and psychotic illnesses, particularly schizophrenia.
www.nature.com/npp/index.html

Brainpod: Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders?

There has been a recent and notable increase in the non-medical use of new psychoactive substances (NPS), or "designer drugs." Unlike classic drugs of abuse, many NPS were initially developed for research purposes. In this podcast, Drs. Michael Baumann and Nora Volkow discuss the complexities of working with these substances and how, given their genesis, research with NPS could be considered "dual use;" or, potentially utilized for both beneficial and malicious purposes.
www.nature.com/npp/index.html

Brainpod: Abuse of New Psychoactive Substances: Threats and Solutions

"Impact of Stress on the Brain: Pathology, Treatment and Prevention," the 2016 issue of Neuropsychopharmacology Reviews, focuses on advances in our understanding of the impact of stress on the brain: From pathology to circuits, treatment to prevention. Emerging data from genetics, epigenetics, neural circuit and intergenerational models, animal models, and neuroimaging all suggest that stress affects the brain in a variety of dynamic and often long-lasting ways. The effects of these processes on developmental risk for pathology are particularly notable.
www.nature.com/npp/index.html

Brainpod: Impact of Stress on the Brain: Pathology, Treatment and Prevention

There's a technology that's proven to be increasingly useful in the past decade — it's called DREADD, or "designer receptors exclusively activated by designer drugs." The current approach is to create a designer receptor that is unlocked by the drug, clozapine-n-oxide, or CNO. Researchers have used it to study the function of populations of neurons or of particular pathways in the brains in rodents, by using the DREADD technique to turn on and off these neurons or pathways. However, last year, a paper published in the journal Science called the use of DREADDs into question. Some people interpreted the paper as an overall indictment of the DREADD technology, though this wasn't the original intent of the authors. Listen to Neuropsychopharmacology's latest podcast to learn more!

Article link:
https://www.nature.com/articles/npp2017299

Brainpod March 2018: Considerations for the Use of DREADDs in Behavioral Neuroscience

Welcome to the Springer Nature Soundcloud page! Here you will find several podcasts from our journals across a range of scientific subjects, including Gene Pod, ModPath Chat, Pediapod, Hereditypod and Brainpod.

Brainpod March 2018: Considerations for the Use of DREADDs in Behavioral Neuroscience

Springer Nature

Related tracks